Background: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on reducing the risk of stroke in patients with type 2 diabetes mellitus (T2DM) remains unclear. Thus, we conducted this systemic review and meta-analysis of all relevant studies and trials to explore the role of SGLT2 inhibitors on the stroke prevention. Methods: The present study included articles published before October 2021 and searched in Web of Science, PubMed databases. We used STATA 12.0 software to compute hazard ratio (HR) and 95% confidence interval (CI). Results: Meta-analysis indicated that SGLT2 inhibitors showed no significant effects on risk of stroke in diabetes in randomized controlled trials with a fixed effects model (HR = 0.98; 95% CI: 0.88–1.09, I2 = 22.3%, p = 0.272). Compared to other glucose-lowering drugs (oGLD) and insulin, SGLT2 inhibitors alone significantly affected risk of stroke in diabetes in observational studies with a random effects model (HR = 0.87; 95% CI: 0.80–0.95, I2 = 72.2%, p < 0.001). Conclusions: In summary, this meta-analysis indicated that the use of SGLT2 inhibitors did not decrease the risk of stroke. And for some T2DM patients with high-risk factor of stroke, SGLT2 inhibitors therapy may be more suitable compared to some oGLD such as dipeptidyl peptidase-4 inhibitors. The results of this meta-analysis are necessary to be confirmed with further studies and clinical trials.

1.
Cho
NH
,
Shaw
JE
,
Karuranga
S
,
Huang
Y
,
da Rocha Fernandes
JD
,
Ohlrogge
AW
,
IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045
.
Diabetes Res Clin Pract
.
2018 Apr
;
138
:
271
81
.
2.
Zheng
Y
,
Ley
SH
,
Hu
FB
.
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
.
Nat Rev Endocrinol
.
2018 Feb
;
14
(
2
):
88
98
. .
3.
Herman
WH
.
The global agenda for the prevention of type 2 diabetes
.
Nutr Rev
.
2017 Jan
;
75
(
Suppl 1
):
13
8
. .
4.
Magliano
DJ
,
Islam
RM
,
Barr
ELM
,
Gregg
EW
,
Pavkov
ME
,
Harding
JL
,
Trends in incidence of total or type 2 diabetes: systematic review
.
BMJ (Clinical research ed)
.
2019 Sep 11
;
366
:
l5003
.
5.
Yun
H
,
Sun
L
,
Wu
Q
,
Zong
G
,
Qi
Q
,
Li
H
,
Associations among circulating sphingolipids, β-cell function, and risk of developing type 2 diabetes: a Population-Based Cohort Study in China
.
PLoS Med
.
2020 Dec
;
17
(
12
):
e1003451
.
6.
Braunwald
E
.
Diabetes, heart failure, and renal dysfunction: the vicious circles
.
Prog Cardiovasc Dis
.
2019 Jul-Aug
;
62
(
4
):
298
302
. .
7.
Taylor
SI
,
Blau
JE
,
Rother
KI
.
SGLT2 inhibitors may predispose to ketoacidosis
.
J Clin Endocrinol Metab
.
2015 Aug
;
100
(
8
):
2849
52
. .
8.
Mahaffey
KW
,
Jardine
MJ
,
Bompoint
S
,
Cannon
CP
,
Neal
B
,
Heerspink
HJL
,
Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups
.
Circulation
.
2019 Aug 27
;
140
(
9
):
739
50
.
9.
Neal
B
,
Perkovic
V
,
Mahaffey
KW
,
de Zeeuw
D
,
Fulcher
G
,
Erondu
N
,
Canagliflozin and cardiovascular and renal events in type 2 diabetes
.
N Engl J Med
.
2017 Aug 17
;
377
(
7
):
644
57
.
10.
Zinman
B
,
Wanner
C
,
Lachin
JM
,
Fitchett
D
,
Bluhmki
E
,
Hantel
S
,
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
.
N Engl J Med
.
2015 Nov 26
;
373
(
22
):
2117
28
.
11.
Wiviott
SD
,
Raz
I
,
Bonaca
MP
,
Mosenzon
O
,
Kato
ET
,
Cahn
A
,
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
.
N Engl J Med
.
2019 Jan 24
;
380
(
4
):
347
57
.
12.
Kosiborod
M
,
Lam
CSP
,
Kohsaka
S
,
Kim
DJ
,
Karasik
A
,
Shaw
J
,
Cardiovascular events associated With SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study
.
J Am Coll Cardiol
.
2018 Jun 12
;
71
(
23
):
2628
39
.
13.
Han
SJ
,
Ha
KH
,
Lee
N
,
Kim
DJ
.
Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a Nationwide Population-Based Study
.
Diabetes Obes Metab
.
2021 Mar
;
23
(
3
):
682
91
. .
14.
Moher
D
,
Liberati
A
,
Tetzlaff
J
,
Altman
DG
.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
.
BMJ
.
2009 Jul 21
;
339
(
7
):
b2535
. .
15.
Zinman
B
,
Inzucchi
SE
,
Lachin
JM
,
Wanner
C
,
Fitchett
D
,
Kohler
S
,
Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk
.
Stroke
.
2017 May
;
48
(
5
):
1218
25
.
16.
Wiviott
SD
,
Raz
I
,
Bonaca
MP
,
Mosenzon
O
,
Kato
ET
,
Cahn
A
,
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
.
N Engl J Med
.
2019 Jan 24
;
380
(
4
):
347
57
.
17.
Zhou
Z
,
Lindley
RI
,
Rådholm
K
,
Jenkins
B
,
Watson
J
,
Perkovic
V
,
Canagliflozin and stroke in type 2 diabetes mellitus
.
Stroke
.
2019 Feb
;
50
(
2
):
396
404
.
18.
Cannon
CP
,
Pratley
R
,
Dagogo-Jack
S
,
Mancuso
J
,
Huyck
S
,
Masiukiewicz
U
,
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
.
N Engl J Med
.
2020 Oct 8
;
383
(
15
):
1425
35
.
19.
Zhou
Z
,
Jardine
MJ
,
Li
Q
,
Neuen
BL
,
Cannon
CP
,
de Zeeuw
D
,
Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis
.
Stroke
.
2021 May
;
52
(
5
):
1545
56
.
20.
Birkeland
KI
,
Jørgensen
ME
,
Carstensen
B
,
Persson
F
,
Gulseth
HL
,
Thuresson
M
,
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
.
Lancet Diabetes Endocrinol
.
2017 Sep
;
5
(
9
):
709
17
.
21.
Kosiborod
M
,
Birkeland
KI
,
Cavender
MA
,
Fu
AZ
,
Wilding
JP
,
Khunti
K
,
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL Study
.
Diabetes Obes Metab
.
2018 Aug
;
20
(
8
):
1983
7
.
22.
O’Brien
MJ
,
Karam
SL
,
Wallia
A
,
Kang
RH
,
Cooper
AJ
,
Lancki
N
,
Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes
.
JAMA Netw Open
.
2018 Dec 7
;
1
(
8
):
e186125
.
23.
Patorno
E
,
Goldfine
AB
,
Schneeweiss
S
,
Everett
BM
,
Glynn
RJ
,
Liu
J
,
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: Population Based Cohort Study
.
BMJ
.
2018 Feb 6
;
360
:
k119
.
24.
Persson
F
,
Nyström
T
,
Jørgensen
ME
,
Carstensen
B
,
Gulseth
HL
,
Thuresson
M
,
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a Multinational Observational Study
.
Diabetes Obes Metab
.
2018 Feb
;
20
(
2
):
344
51
.
25.
Udell
JA
,
Yuan
Z
,
Rush
T
,
Sicignano
NM
,
Galitz
M
,
Rosenthal
N
.
Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL Population-Based Cohort Study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)
.
Circulation
.
2018 Apr 3
;
137
(
14
):
1450
9
. .
26.
Norhammar
A
,
Bodegård
J
,
Nyström
T
,
Thuresson
M
,
Nathanson
D
,
Eriksson
JW
.
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a Nationwide Observational Study
.
Diabetes Obes Metab
.
2019
;
21
(
5
):
1136
. .
27.
Pasternak
B
,
Ueda
P
,
Eliasson
B
,
Svensson
AM
,
Franzén
S
,
Gudbjörnsdottir
S
,
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: scandinavian register based cohort study
.
BMJ
.
2019 Aug 29
;
366
:
l4772
.
28.
Filion
KB
,
Lix
LM
,
Yu
OH
,
Dell’Aniello
S
,
Douros
A
,
Shah
BR
,
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: Multi-Database Retrospective Cohort Study
.
BMJ
.
2020 Sep 23
;
370
:
m3342
.
29.
Han
SJ
,
Ha
KH
,
Lee
N
,
Kim
DJ
.
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: a Nationwide Population‐Based Study
.
Diabetes Obes Metab
.
2020
;
23
(
3
):
682
91
.
30.
Kohsaka
S
,
Lam
CSP
,
Kim
DJ
,
Cavender
MA
,
Norhammar
A
,
Jørgensen
ME
,
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 Multinational Cohort Study
.
Lancet Diabetes Endocrinol
.
2020 Jul
;
8
(
7
):
606
15
.
31.
Lee
HF
,
Chen
SW
,
Liu
JR
,
Li
PR
,
Wu
LS
,
Chang
SH
,
Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
.
Cardiovasc Diabetol
.
2020 Sep 30
;
19
(
1
):
160
.
32.
Longato
E
,
Camillo
BD
,
Sparacino
G
,
Gubian
L
,
Fadini
GP
.
Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
.
BMJ Open Diabetes Res Care
.
2020
;
8
(
1
):
e001451
.
33.
Tien-Hsing
C
,
Yan-Rong
L
,
Shao-Wei
C
,
Yu-Sheng
L
,
Chi-Chin
S
,
Dong-Yi
C
,
Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a Multi-Institution Database Study
.
Cardiovasc diabetol
.
2020
;
19
(
1
):
189
.
34.
Birkeland
KI
,
Bodegard
J
.
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: a Large Multinational Observational Study
.
Diabetes Obes Metab
.
2021 Jan
;
23
(
1
):
75
85
.
35.
Dave
CV
,
Kim
SC
,
Goldfine
AB
,
Glynn
RJ
,
Tong
A
,
Patorno
E
.
Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy
.
Circulation
.
2021 Feb 23
;
143
(
8
):
770
9
. .
36.
Idris
I
,
Zhang
R
,
Mamza
JB
,
Ford
M
,
Morris
T
,
Banerjee
A
,
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a Retrospective Cohort Study in UK primary care
.
Diabetes Obes Metab
.
2021 Oct
;
23
(
10
):
2207
14
.
37.
Komuro
I
,
Kadowaki
T
,
Bodegård
J
.
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases
.
Diabetes Obes Metab
.
2021 Apr
;
23
(
Suppl 2
):
19
27
. .
38.
Lugner
M
,
Sattar
N
,
Miftaraj
M
,
Ekelund
J
,
Franzén
S
,
Svensson
AM
,
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: Nationwide Observational Study
.
Cardiovasc Diabetol
.
2021 Mar 22
;
20
(
1
):
67
.
39.
Real
J
,
Vlacho
B
,
Ortega
E
,
Vallés
JA
,
Mata-Cases
M
,
Castelblanco
E
,
Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-real catalonia
.
Cardiovasc Diabetol
.
2021 Jul 9
;
20
(
1
):
139
.
40.
Wong
CKH
,
Tang
EHM
,
Man
KKC
,
Chan
EWY
,
Wong
ICK
,
Lam
CLK
.
SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus
.
Diabetes Metab
.
2021 Jul
;
47
(
4
):
101196
. .
41.
Guo
M
,
Ding
J
,
Li
J
,
Wang
J
,
Zhang
T
,
Liu
C
,
SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: a systematic review and meta-analysis
.
Diabetes Obes Metab
.
2018 Aug
;
20
(
8
):
1977
82
.
42.
Tsai
WH
,
Chuang
SM
,
Liu
SC
,
Lee
CC
,
Chien
MN
,
Leung
CH
,
Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
.
Sci Rep
.
2021 Jul 28
;
11
(
1
):
15364
.
43.
Zou
CY
,
Liu
XK
,
Sang
YQ
,
Wang
B
,
Liang
J
.
Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis
.
Medicine
.
2019 Dec
;
98
(
49
):
e18245
. .
44.
Zheng
SL
,
Roddick
AJ
,
Aghar-Jaffar
R
,
Shun-Shin
MJ
,
Francis
D
,
Oliver
N
,
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis
.
JAMA
.
2018 Apr 17
;
319
(
15
):
1580
91
.
45.
Palmer
SC
,
Tendal
B
,
Mustafa
RA
,
Vandvik
PO
,
Li
S
,
Hao
Q
,
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.
BMJ
.
2021 Jan 13
;
372
:
m4573
.
46.
Zannad
F
,
Ferreira
JP
,
Pocock
SJ
,
Anker
SD
,
Butler
J
,
Filippatos
G
,
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials
.
Lancet
.
2020 Sep 19
;
396
(
10254
):
819
29
.
47.
McGuire
DK
,
Shih
WJ
,
Cosentino
F
,
Charbonnel
B
,
Cherney
DZI
,
Dagogo-Jack
S
,
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
.
JAMA Cardiol
.
2021 Feb 1
;
6
(
2
):
148
58
.
48.
Oelze
M
,
Kröller-Schön
S
,
Welschof
P
,
Jansen
T
,
Hausding
M
,
Mikhed
Y
,
The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity
.
PLoS One
.
2014
;
9
(
11
):
e112394
.
49.
Rahadian
A
,
Fukuda
D
,
Salim
HM
,
Yagi
S
,
Kusunose
K
,
Yamada
H
,
Canagliflozin prevents diabetes-induced vascular dysfunction in ApoE-deficient mice
.
J Atheroscler Thromb
.
2020 Nov 1
;
27
(
11
):
1141
51
.
50.
Day
EA
,
Ford
RJ
,
Lu
JH
,
Lu
R
,
Lundenberg
L
,
Desjardins
EM
,
The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice
.
Biochem J
.
2020 Jun 26
;
477
(
12
):
2347
61
.
51.
Zelniker
TA
,
Braunwald
E
.
Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review
.
J Am Coll Cardiol
.
2020 Feb 4
;
75
(
4
):
422
34
. .
52.
Zhang
Y
,
Nakano
D
,
Guan
Y
,
Hitomi
H
,
Uemura
A
,
Masaki
T
,
A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice
.
Kidney Int
.
2018 Sep
;
94
(
3
):
524
35
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.